Possibility to use barycytinib in patients with COVID-19, including for treatment of «cytokine storm»

Possibility to use barycytinib in patients with COVID-19, including for treatment of «cytokine storm»

Until clinical trials of efficacy and safety are obtained, routine use of barycytinib in patients with COVID-19 cannot be recommended.

Bibliographic Details
Main Authors:	V. A. Otdelenov, V. M. Tsvetov, D. A. Sychev
Format:	Article
Language:	Russian
Published:	Izdatelstvo OKI 2020-10-01
Series:	Качественная клиническая практика
Subjects:	коронавирус барицитиниб covid-19 цитокиновый шторм
Online Access:	https://www.clinvest.ru/jour/article/view/517

Similar Items

Current and future use of aminodihydrophthalazindione sodium in patients with COVID-19, including for «cytokine storm» therapy
by: V. M. Tsvetov, et al.
Published: (2020-10-01)

MECHANISMS OF CYTOKINE STORM DEVELOPMENT IN COVID-19 AND NEW POTENTIAL TARGETS OF PHARMACOTHERAPY
by: V. I. Petrov, et al.
Published: (2021-05-01)

The Role of Ferritin in Assessing COVID-19 Severity
by: Yu. S. Polushin, et al.
Published: (2021-08-01)

КРИТЕРИИ ЭФФЕКТИВНОСТИ ПРОЦЕДУРЫ ГЕМОСОРБЦИИ ПРИ ЛЕЧЕНИИ ПАЦИЕНТОВ С ТЯЖЕЛЫМ ТЕЧЕНИЕМ COVID-19
by: Сергей Григорьевич Щербак, et al.
Published: (2022-11-01)

СORONAVIRUS INFECTION WITH AN OBESITY
by: S. N. Ionov, et al.
Published: (2021-07-01)

Changes in the levels of some cytokines when using blood purification in COVID-19 patients
by: Yu. S. Polushin, et al.
Published: (2021-05-01)

Possibilities for the use of anakinra in COVID-19
by: V. A. Otdelenov, et al.
Published: (2020-10-01)

Is there a connection between iron exchange and COVID-19?
by: Yu. P. Orlov, et al.
Published: (2020-09-01)

Биологическая роль, свойства и клиническое значение мелатонина при инфекции, вызванной вирусом SARS-Cov-2
by: Аксаамай Эмиловна Орозалиева, et al.
Published: (2022-02-01)

Successful treatment of a severe course of coronavirus infection in the obese polymorbid patient after bariatric surgery
by: I. P. Siutkina, et al.
Published: (2022-07-01)

Было ли широко распространено неадекватное лечение тяжелых случаев КОВИД-19? МНЕНИЕ педиатра ревматолога
by: Роберт Реннебом
Published: (2020-12-01)

Применение мезенхимальных стволовых клеток в лечении тяжелых форм новой коронавирусной инфекции COVID-19: проспективное наблюдательное исследование
by: Aleksandr M. Dzyadzko, et al.
Published: (2023-01-01)

Is it possible to use riamilovir to prevent infection and treat COVID-19?
by: V. M. Tsvetov, et al.
Published: (2020-10-01)

Rationality of routine clinical use of olokizumab in COVID-19
by: V. M. Tsvetov, et al.
Published: (2020-10-01)

Could canakinumab be used for COVID-19?
by: V. A. Otdelenov, et al.
Published: (2020-10-01)

Dexamethasone use in patients with COVID-19
by: V. A. Otdelenov, et al.
Published: (2020-10-01)

Possibility to use direct oral anticoagulants to prevent thromboembolic events in patients with COVID-19
by: V. A. Otdelenov, et al.
Published: (2020-10-01)

Current and future use of remdesivir in patients with COVID-19
by: V. M. Tsvetov, et al.
Published: (2020-10-01)

Coronavirus Infection an Obese Patient (Literature Review)
by: E. I. Panova, et al.
Published: (2021-05-01)

Current and future use of umifenovir in patients with COVID-19
by: Yu. Yu. Kiselev, et al.
Published: (2020-10-01)

Possibilities for the use of hydroxychloroquine for pre- and postexposure prophylaxis of SARS-CoV-2 infection among exposed contacts and healthcare personnel
by: V. A. Otdelenov, et al.
Published: (2020-10-01)

Current and future use of dipyridamole in patients with COVID-19
by: I. S. Burashnikova, et al.
Published: (2020-10-01)

Rationale for use mefloquine for COVID-19 treatment
by: V. A. Otdelenov, et al.
Published: (2020-10-01)

Possibilities for the use of tofacitinib in patients with COVID-19
by: A. V. Matveev, et al.
Published: (2020-10-01)

ВЗАИМОСВЯЗЬ ГИПЕРАКТИВАЦИИ СИГНАЛЬНОГО ПУТИ mTOR, ПРОЦЕССОВ СТАРЕНИЯ И ПАТОГЕНЕЗА COVID-19 (ОБЗОР ЛИТЕРАТУРЫ)
by: И.А. Баранов, et al.
Published: (2023-08-01)

Anticoagulant deprescribing algorithm in patients with COVID-19 after hospital discharge
by: A. V. Krykov, et al.
Published: (2020-10-01)

Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis
by: V. M. Tsvetov, et al.
Published: (2020-10-01)

Hemoadsorption in Patients with Various Types of Respiratory Support for Severe COVID-19
by: R. E. Yakubtsevich, et al.
Published: (2022-10-01)

Acute coronary syndrome in COVID-19 patients
by: M. G. Chashchin, et al.
Published: (2021-09-01)

EFFICACY AND SAFETY OF ORIGINAL DRUG BASED ON HEXAPEPTIDE SUCCINATE IN COMPLEX COVID-19 THERAPY IN ADULTS HOSPITALIZED PATIENTS
by: L. A. Balykova, et al.
Published: (2023-02-01)

Current and future use of angiotensin II receptor blockers in patients with COVID-19
by: A. V. Matveev, et al.
Published: (2020-10-01)

Цитокин-опосредованная дисрегуляция иммунного ответа при инфицировании SARS-CoV-2 (обзор)
by: Aleksey A. Artemenkov
Published: (2023-10-01)

Current and future use of colchicine in patients with COVID-19
by: Yu. Yu. Kiselev, et al.
Published: (2020-10-01)

Current and future use of favipiravir in patients with COVID-19
by: A. V. Matveev, et al.
Published: (2020-10-01)

COMPARATIVE ANALYSIS OF DRUG EFFICACY IN THE TREATMENT FOR COVID-19 SEVERE FORMS, BASED ON ATTRIBUTE-BASED STATISTIC METHODS AND ANALYSIS OF DRUG INTERACTIONS
by: O. V. Zhukova, et al.
Published: (2021-03-01)

Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19
by: V. A. Otdelenov, et al.
Published: (2020-10-01)

Current and future use of vitamin D<sub>3</sub> in patients with COVID-19
by: I. N. Sychev, et al.
Published: (2020-10-01)

Change of opinion on the use of hydroxychloroquine for COVID-19 treatment and prevention
by: K. B. Mirzaev, et al.
Published: (2020-10-01)

Possibility for the use of bromhexine to prevent infection with SARS-CoV-2
by: K. A. Zagorodnikova, et al.
Published: (2020-10-01)

Methylprednisolone in acute respiratory distress-syndrome in COVID-19: rationales for use, optimal dosage regimens, combined use with tocilizumab
by: K. B. Mirzaev, et al.
Published: (2020-10-01)